Penumbra has announced the launch of the Lantern microcatheter at the upcoming Society of Interventional Radiology annual scientific meeting (SIR 2016, 2-7 April, Vancouver, Canada).
Lantern is a low profile, high flow microcatheter designed to assist in the delivery of diagnostic agents, such as contrast media, and therapeutic devices, such as occlusion coils, to the peripheral vasculature. It adds to Penumbra’s growing embolization portfolio, as it aids in the delivery of Penumbra’s embolization devices, including the Ruby coil, POD (Penumbra Occlusion Device) and POD packing coil.
Lantern received 510(k) clearance from the US FDA in December 2015. It is offered in a variety of lengths and tip shapes relevant to peripheral vascular procedures. Lantern’s distal segment is visible under fluoroscopy to aid in the navigation and visualisation of the microcatheter during procedures.
“Like many Penumbra products, the Lantern microcatheter is unique in its design and helps address physician needs for a low profile, high flow microcatheter,” said Adam Elsesser, chairman and CEO of Penumbra. “It is designed to track distally through the peripheral vasculature, yet can be used for high flow contrast injections, combining these desired properties into one microcatheter.”
In addition, the final results of the multicentre PRISM study, designed to assess the safety and efficacy of the Indigo system for peripheral and visceral arterial thrombi and emboli, will be presented. The Indigo system is a novel mechanical aspiration system for the removal of emboli and thrombi in the peripheral vasculature.
The final results of the PRISM study will be presented at SIR 2016 by Corey Teigen, Sanford Health, Fargo, USA. PRISM, which began in 2014, sought to evaluate the use of the Indigo System for patients with peripheral occlusions secondary to acute ischaemia, incomplete reperfusion, and procedure-related distal emboli, using primarily the smaller size catheters of the Indigo System.
“Penumbra/Indigo System provides a novel aspiration thrombectomy tool in treatment of peripheral and visceral arterial occlusions – final results of the PRISM trial” will be presented Monday, 4 April at 1500 hours.
